369
Views
9
CrossRef citations to date
0
Altmetric
CASE REPORT

Rifampin Reduces Oral Morphine Absorption: A Case of Transdermal Buprenorphine Selection Based on Morphine Pharmacokinetics

, &
Pages 362-367 | Published online: 07 Dec 2012

REFERENCES

  • Fudin J. Opioid pharmacokinetics and expected metabolites. 2011. Available at: http: //paindr.com/wp-content/uploads/ 2012/05/Opioid-Serum-Predictability-and-Metabolites.pdf. Accessed August 27, 2012.
  • Pharmacist's letter. Drug interactions. 2012. Available at: http: //pharmacistsletter.therapeut icresearch.com/pl/ ArticleDD.aspx?nidchk=1&cs=STUDENT&s=PL&pt=6& fpt=31&dd=260603&pb=PL&searchid=36715122. Accessed August 24, 2012.
  • Baumann TJ, Strickland JM, Herndon CM. Pain management. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011: 989–1003.
  • Interaction: Morphine, Rifampin. In: LexiComp Online [database on the Internet]. Hudson, OH: Lexi-Comp, Inc.; 2012. Available at: http://online.lexi.com/lco/action/interact. Accessed September 12, 2012. [Subscription required to view.]
  • Interaction: Morphine, Rifampin. In: Micromedex Online [database on the Internet]. Greenwood Village, CO: Thompson Micromedex; 1974–2012. Available at: www.micromedex.com. Accessed September 12, 2012. [Subscription required to view.]
  • Fromm MF, Eckhardt K, Li S, Loss of analgesic effect of morphine due to coadministration of rifampin. Pain. 1997;72:261–267.
  • Cavallari LH, Lam YW. Pharmacogenetics. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed.; 2011. Available at: http://www.accesspharmacy.com/ content.aspx?aID=7966967. Accessed August 24, 2012.
  • Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther. 2003;74:543–554.
  • Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147–153.
  • Coluzzi F., Pappagallo M. Opioid therapy for chronic non cancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;425–433.
  • Weissman DE, Haddox JD. Opioid pseudoaddiction—an iatrogenic syndrome. Pain. 1989;36:363–366.
  • Fudin J, Levasseur DJ, Passik SD, Kirsh KL, Coleman J. Chronic pain management with opioids in patients with past or current substance abuse problems. J Pharm Pract. 2003;16:291–308.
  • Butrans: Buprenorphine Transdermal Patch [package insert]. Stamford, CT: Purdue Pharma; 2010.
  • Pharmacist's Letter. Cytochrome P450 interactions. 2012. Available at: http: //pharmacistsletter.therapeuticresearch. com/pl/ArticleDD.aspx?nidchk=1&cs=PLPHONLY_NDALL_ LI&s=PL&pt=6&fpt=31&dd=260112&pb=PL&cat=4302. Accessed August 24, 2012.
  • Donnelly S, Davis MP, Walsh D. World Health Organization. Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10:13–35.
  • Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatr. 1978;35:501–516.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.